Journal ArticleOPEN ACCESS

Use of REGEN-COV in children after heart transplantation for treatment and post-exposure prophylaxis of COVID-19

Cardiology in the Young (2023) 33(3) 496-497
DOI: 10.1017/S1047951122002190
2Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.

Abstract

COVID-19 pandemic continues to evolve and new variants like Delta and Omicron have been discovered. REGEN-COV is a recombinant human monoclonal antibody to the spike protein of SARS-CoV-2 which received emergency use authorisation for treatment and post-exposure prophylaxis in patients with high risk of progression to severe disease. We review our experience with use of REGEN-COV in paediatric heart transplant patients.

Author supplied keywords

Cite

CITATION STYLE

APA

Gupta, D., Clifford, S. A., & Fricker, F. J. (2023). Use of REGEN-COV in children after heart transplantation for treatment and post-exposure prophylaxis of COVID-19. Cardiology in the Young, 33(3), 496–497. https://doi.org/10.1017/S1047951122002190

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free